Latest Breaking News On - Christos sotiriou - Page 1 : comparemela.com

PDC*line Pharma and Partners Receive €8 1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project

PDC*line Pharma and Partners Receive €8 1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Saint lucHaute normandieWaals gewestSouth koreaWalloon regionBruxelles capitaleUnited kingdomEric haliouaStefan klotterJean pol detiffeInstitut jules bordetClaude dedryJean pascal machielsUclouvain cliniquesFrancesco sclafaniSaffiyah khalique juliette schmitt

How Vodafone Greece Built 80 Java Microservices in Quarkus – The New Stack

How Vodafone Greece Built 80 Java Microservices in Quarkus – The New Stack
thenewstack.io - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thenewstack.io Daily Mail and Mail on Sunday newspapers.

Red hatAmazon web servicesHow sotiriou team uses quarkusChristos sotiriouVodafone greeceBackend chapter leadAmazon webJava spring bootJava applicationsSpring bootQuarkus springசிவப்பு தொப்பிஅமேசான் வலை சேவைகள்வோடபோன் கிரீஸ்அமேசான் வலைஜாவா வசந்த துவக்க

Osteoporosis drug also promotes infiltration of immune cells in breast tumors

Osteoporosis drug also promotes infiltration of immune cells in breast tumors The team of Eva González-Suarez, from the CNIO and IDIBELL, and the team of Christos Sotiriou, from the Jules Bordet Institute, demonstrate that a drug already used to treat osteoporosis promotes the infiltration of immune cells in breast tumors These findings propose a new target to increase the antitumor immune response and make breast cancer more sensitive to immunotherapy Despite the success of immunotherapy in the treatment of cancers such as lung or melanoma, it is still not effective in breast cancers for being cold , with low infiltration of immune cells.

Investigaciones oncologicasEva gonzEva gonzalez suarezEmily hendersonNature communicationsBellvitge institute for biomedical researchSpanish national cancer research centerMetastasis groupJules bordet instituteChristos sotiriouBellvitge instituteBiomedical researchCentro nacional de investigacionesஈவா கோன்ஸ்ஈவா கோன்சலஸ் ஸ்யூவாரெஸ்எமிலி ஹென்டர்சன்

The immunomodulatory activity of a drug would improve the efficacy of immunotherapy in breast cancer

Credit: IDIBELL Despite the success of immunotherapy in the treatment of cancers such as lung or melanoma, it is still not effective in breast cancers for being cold , with low infiltration of immune cells. Tumours use strategies to evade immune surveillance by reducing the infiltration of cells that could attack them or by attracting immunosuppressive cells. These strategies can contribute to the poor prognosis observed in breast cancer of young women and make them unresponsive to immunotherapy. For this reason, the identification of a therapy that could convert immunologically cold tumours -in which immunotherapy is not effective- into warm tumours would represent an important step to increase the efficiency of immunological therapies for breast cancer, since these are based on the reactivation of immune cells to attack tumour cells.

Eva gonzalez suarezEuropean regional development fundNational fund for scientific research of belgiumNature communicationsSpanish national cancer research centerJules bordet instituteBellvitge institute for biomedical researchMetastasis groupEuropean research agencyNational institute of health carlosUs national institutes of healthMinistry of scienceBellvitge instituteBiomedical researchChristos sotiriouNational institute